All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tofacitinib Citrate
Therapeutic Area: Dermatology Product Name: AC-1101
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 07, 2020
Details:
Health Canada has approved Ancheng Biotech's open-label, fixed-sequence, two-period, comparative bioavailability study of AC-1101 (Tofacitinib Citrate). Tofacitinib Citrate is a topical JAK inhibitor for the treatment of vitiligo.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
